This HTML5 document contains 49 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n12http://linked.opendata.cz/resource/drugbank/drug/DB05076/identifier/chemspider/
n18http://linked.opendata.cz/resource/mesh/concept/
n9http://linked.opendata.cz/resource/drugbank/drug/DB05076/identifier/wikipedia/
n7http://bio2rdf.org/drugbank:
n14http://linked.opendata.cz/resource/drugbank/drug/DB05076/identifier/pdb/
admshttp://www.w3.org/ns/adms#
n16http://linked.opendata.cz/resource/drugbank/drug/DB05076/identifier/pubchem-compound/
n4http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n13http://linked.opendata.cz/resource/drugbank/drug/DB05076/identifier/pubchem-substance/
n5http://linked.opendata.cz/ontology/drugbank/
n17http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n11http://linked.opendata.cz/resource/drugbank/drug/DB05076/identifier/kegg-drug/
n10http://linked.opendata.cz/resource/drugbank/drug/DB05076/identifier/drugbank/
n6http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB05076
rdf:type
n5:Drug
n5:description
A synthetic retinoid that is used orally as a chemopreventive against prostate cancer and in women at risk of developing contralateral breast cancer. It is also effective as an antineoplastic agent.
n5:generalReferences
# Formelli F, Cavadini E, Luksch R, Garaventa A, Villani MG, Appierto V, Persiani S: Pharmacokinetics of oral fenretinide in neuroblastoma patients: indications for optimal dose and dosing schedule also with respect to the active metabolite 4-oxo-fenretinide. Cancer Chemother Pharmacol. 2007 Dec 8;. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18066548 # Takahashi N, Watanabe Y, Maitani Y, Yamauchi T, Higashiyama K, Ohba T: p-Dodecylaminophenol derived from the synthetic retinoid, fenretinide: antitumor efficacy in vitro and in vivo against human prostate cancer and mechanism of action. Int J Cancer. 2008 Feb 1;122(3):689-98. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17955489 # Simeone AM, Tari AM: How retinoids regulate breast cancer cell proliferation and apoptosis. Cell Mol Life Sci. 2004 Jun;61(12):1475-84. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15197471
n5:group
investigational
n5:indication
Investigated for use/treatment in macular degeneration.
owl:sameAs
n4:DB05076 n7:DB05076
dcterms:title
Fenretinide
adms:identifier
n9:Fenretinide n10:DB05076 n11:D04162 n12:4450416 n13:10388780 n14:FEN n16:5288209
n5:mechanismOfAction
Fenretinide inhibits the growth of several human cancer cell lines, acting through both retinoid-receptor-dependent and retinoid-receptor-independent mechanisms.1In vivo, fenretinide selectively accumulates in breast tissue and is particularly active in inhibiting rat mammary carcinogenesis.1 An important feature of fenretinide is its ability to inhibit cell growth through the induction of apoptosis rather than through differentiation, an effect that is strikingly different from that of vitamin A.1 In contrast to tamoxifen, which inhibits only estrogen receptor (ER)-positive tumors, fenretinide induces apoptosis in both ER-positive and ER-negative breast cancer cell lines.2 All of these properties render fenretinide an attractive candidate for breast cancer chemoprevention.
n5:synonym
N-(4-Hydroxyphenyl)All-Trans Retinamide 4-hydroxy(phenyl)retinamide 4-HPR
n5:toxicity
"Mechanism of fenretinide (4-HPR)-induced cell death"
n17:hasConcept
n18:M0026291
n5:IUPAC-Name
n6:271B632E-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B6334-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B6333-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B6330-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B6331-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B6332-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n6:271B632C-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B632A-363D-11E5-9242-09173F13E4C5 n6:271B632D-363D-11E5-9242-09173F13E4C5
n5:logS
n6:271B632B-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Acceptor-Count
n6:271B633A-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B633B-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B6335-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B6336-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B6338-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B6337-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B6339-363D-11E5-9242-09173F13E4C5
n5:casRegistryNumber
65646-68-6
n5:category
n5:Bioavailability
n6:271B6340-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B6342-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B6343-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B633F-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B633E-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B6341-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B632F-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n6:271B633C-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n6:271B633D-363D-11E5-9242-09173F13E4C5